Sign in

Cancer Therapy Advisor

@cancertherapyadv.bsky.social
300 followers 627 following 854 posts

CancerTherapyAdvisor.com is a resource offering oncology health care professionals practical information about the changing clinical landscape.

PostsRepliesMedia
Cancer Therapy Advisor @cancertherapyadv.bsky.social · 12h
Does drinking coffee prevent cancer? A growing body of research might be able to answer this age old question ☕ Check out our feature article: bit.ly/4ycSjK7 #Cancer #Coffee
bit.ly
Does Drinking Coffee Prevent Cancer?
Habitual coffee drinking may have protective effects against various types of cancer, according to a growing body of research.
000
Cancer Therapy Advisor @cancertherapyadv.bsky.social · 08/10/2026
Our advisory board member @lungoncdoc.bsky.socialc recently spoke with us on his top picks of "practice-changing data" from the #WCLC26 Dr Singhi discusses several studies including ADAURA, HARMONi-2, and MAVERICK! Read all his top picks here🔽 bit.ly/4j9o0QD
bit.ly
WCLC 2026: Dr Eric Singhi Reviews Practice-Changing Data From the Annual Meeting
The WCLC 2026 conference saw updates on new antibody-drug conjugates and treatment protocols for small cell and non-small cell lung cancer.
000
Cancer Therapy Advisor @cancertherapyadv.bsky.social · 08/10/2026
Long-term #Opioid use following definitive radiation or chemoradiation is common among patients with nonmetastatic head and neck cancer, according to research from @jamaotolaryngology.com Read the full article on this study here: bit.ly/3TPQyEe
A graphic titled "By the Numbers" from Cancer Therapy Advisor. It states that 70% of nonmetastatic head and neck cancer patients who received definitive radiation or chemoradiation continued taking opioids 3 months after treatment, according to a study on 750 patients.
000
Cancer Therapy Advisor @cancertherapyadv.bsky.social · 06/10/2026
In September, the @fda.gov approved 5 treatments for a range of cancers: Etcamah, Hyrnuo, Inluriyo, Lyrfigtu, and Welireg💊 Read more about each approval here: bit.ly/4z44Gty
000
Cancer Therapy Advisor @cancertherapyadv.bsky.social · 05/10/2026
Initial treatment with either pembrolizumab or nivolumab leads to similar outcomes for patients with advanced, unresectable, or metastatic #Melanoma, according to research from @JAMANetworkOpen See more data here: bit.ly/4zfGRhp
000
Cancer Therapy Advisor @cancertherapyadv.bsky.social · 02/10/2026
Curious about highlights from #IMS26? We spoke with our advisory board member, Rahul Banerjee, MD, about his takeaways from this year's meeting including the MajesTEC-3 & CERVINO clinical trials! #MultipleMyeloma Check them out here: bit.ly/3TfcB7m
020
Cancer Therapy Advisor @cancertherapyadv.bsky.social · 30/09/2026
It's #RareCancerDay! 🎗️ On Rare Cancer Day, we celebrate the researchers, oncologists, hematologists, and clinical pharmacists dedicated to expanding therapeutic options for every rare tumor type! 🎗️
000
Cancer Therapy Advisor @cancertherapyadv.bsky.social · 28/09/2026
Exposure to potential breast carcinogens is common in the US, with hundreds of chemicals found in consumer products, food and drinking water, and pesticides, according to research published in Environmental Health Perspectives. Read more here: bit.ly/4hxZdTV
bit.ly
Study: Potential Breast Carcinogens Are ‘Ubiquitous’ in the US Environment
In this study, researchers aimed to explore the role of environmental factors in rising breast cancer rates in the United States.
000
Cancer Therapy Advisor @cancertherapyadv.bsky.social · 25/09/2026
September is #GynecologicCancerAwarenessMonth 💜 A recent study has found that those with a BRCA1 or BRCA2 pathogenic germline variant delaying preventative BSO is associated with an increased risk of #OvarianCancer Read the article here: bit.ly/4hLuROO
000
Cancer Therapy Advisor @cancertherapyadv.bsky.social · 24/09/2026
@astro-org.bsky.social recently issued clinical practice guidelines for the use of #RadiationTherapy in #BladderCancer Check out the details of this new guideline here: bit.ly/4dE1Sdp
bit.ly
ASTRO Issues Clinical Practice Guideline for Use of RT in Bladder Cancer
The new clinical guideline was developed by a multidisciplinary task force of radiation, medical, and urologic oncologists, a medical physicist, and a patient representative who reviewed published lit...
000
Cancer Therapy Advisor @cancertherapyadv.bsky.social · 22/09/2026
A study in Cancer analyzing 1,581 male childhood cancer survivors found many underestimate their long-term risk for sexual dysfunction, even after high-risk treatments. Find all the data here: bit.ly/3UZ8Jb3 #PediatricCancer #CancerCare
011
Cancer Therapy Advisor @cancertherapyadv.bsky.social · 21/09/2026
New research presented at #SOHO2026 highlighted key advances in #AML, including the timing of treatment initiation in newly diagnosed AML and as well as the treatment strategies in older or unfit patients. 🔗 Read our feature on all the research here: bit.ly/4rxcErO
bit.ly
SOHO 2026: Treatment Strategies in Acute Myeloid Leukemia
Studies presented at the Society of Hematologic Oncology (SOHO) 2026 Meeting will inform treatment strategies in acute myeloid leukemia.
000
Cancer Therapy Advisor @cancertherapyadv.bsky.social · 18/09/2026
🆕 The latest episode of Val-YOU Based Care hosted by Kimbery Ku is out NOW! Dr Ku speaks with DeepScribe CEO, Matthew Ko, about DeepScribe's mission and how AI is changing #CancerCare ❤️ Full video and transcript available here: bit.ly/4dKyrGx
000
Cancer Therapy Advisor @cancertherapyadv.bsky.social · 18/09/2026
First-line trastuzumab deruxtecan (T-DXd) prolongs PFS, but not overall survival, in metastatic, HER2-mutant #NSCLC Julia Rotow, MD, from @danafarber.bsky.social presented research from the DESTINY-Lung 04 trial this week at #WCLC2026 @iaslc.bsky.social Full article: bit.ly/4gY7oK6
011
Cancer Therapy Advisor @cancertherapyadv.bsky.social · 17/09/2026
More from #WCLC26!🫁 The phase 2 ARROS-1 trial assessed the efficacy and safety of zidesamtinib in patients with advanced/metastatic ROS1+ NSCLC who had not received a TKI. The ORR was 93%, with a 12-month duration of response rate of 86%. Full article: bit.ly/473asPb
000
Cancer Therapy Advisor @cancertherapyadv.bsky.social · 17/09/2026
Pumitamig and elfetabart drozuntecan (elfe-d) showed encouraging early efficacy + managable safety profile for patients with #SCLC The ORR was 70.4% in patients with SCLC irrespective of smoking status or brain metastases. From #WCLC26 Read more here: bit.ly/4iA2vIs
000
Cancer Therapy Advisor @cancertherapyadv.bsky.social · 17/09/2026
Ipilimumab/nivolumab plus local consolidation therapy shortens survival in stage IV #NSCLC Median OS for nivolumab/ipilimumab plus local consolidative therapy was 43.2 months versus 52.8 months without local consolidation therapy #WCLC26 Read: bit.ly/4y0cVWt
000
Cancer Therapy Advisor @cancertherapyadv.bsky.social · 17/09/2026
Updated findings from TRUST-I & TRUST-II were presented in a poster at #WCLC26 🫁 Taletrectinib has shown durable ORRs & a manageable safety profile in patients with ROS1-positive #NSCLC, regardless of ROS1 fusion partners or prior chemo exposure. Read: bit.ly/4y0b18h
000
Cancer Therapy Advisor @cancertherapyadv.bsky.social · 15/09/2026
Phase 3 REZILIENT3 trial results presented at #WCLC2026: Adding the TKI zipalertinib to 1L chemotherapy improves outcomes in EGFR ex20ins #NSCLC: • Median PFS: 14.5 vs 8.5 mos • ORR: 65.0% vs 40.3% • Median DOR: 14.2 vs 9.9 mos Full Article: bit.ly/46pC3Kk
000
Cancer Therapy Advisor @cancertherapyadv.bsky.social · 15/09/2026
Ambient air pollution has been associated with poorer 5-year survival with #LungCancer 🫁 Survival varies differently across populations; non-smokers may be more vulnerable to the effects of pollution. Read all the data on this #WCLC26 presentation here: bit.ly/4hsmwzo
000
Cancer Therapy Advisor @cancertherapyadv.bsky.social · 15/09/2026
‼️ Adding amivantamab to chemo improves OS in #NSCLC who have EGRF ex20ins OS and PFS improved, as well as prolonged time to worsening of symptoms compared w/ chemo alone. Presented by Chul Kim, MD, at the #WCLC26! Full Article: bit.ly/4dD6Hn8
000
Cancer Therapy Advisor @cancertherapyadv.bsky.social · 15/09/2026
The PALOMA-2 trial presented by Misako Nagasaka at #WCLC26 found amivantamab plus lazertinib had clinically meaningful and durable antitumor efficacy for #NSCLC 🫁 Dr Nagasaka spoke with us about the PALOMA-2 trial; see the data and read the article here🔽 bit.ly/4Ajvt5K
000
Cancer Therapy Advisor @cancertherapyadv.bsky.social · 15/09/2026
🆕 NEW from #WCLC26! The phase 3 ADAURA trial found: Patients with stage II-IIIA of EGFR-mutated, early-stage #NSCLC, the 8-year OS was 74% in the osimertinib arm & 58% in the placebo arm. @IASLC Read more data from the study here: bit.ly/4cMq78T
000
Cancer Therapy Advisor @cancertherapyadv.bsky.social · 14/09/2026
New phase 3 ARTEMIS-008 trial results presented at #WCLC2026: Risvutatug rezetecan (ris-rez) significantly improved median overall survival vs. topotecan in relapsed small cell lung cancer (18.5 vs. 10.3 months). 🫁 Read the full article: bit.ly/3URwcuE
000
Cancer Therapy Advisor @cancertherapyadv.bsky.social · 14/09/2026
In the Phase 3 IMpower030 trial presented at #WCLC26, perioperative atezolizumab + chemo more than doubled median EFS in resectable stage IIB–IIIB #NSCLC (62.8 vs 34.9 months; HR 0.77). However, the trial missed its primary endpoint. Link to the article: bit.ly/4xQRIhB
000
Cancer Therapy Advisor @cancertherapyadv.bsky.social · 14/09/2026
Primary analysis of the Phase 2 MDT-BRIDGE study presented at WCLC 2026 shows encouraging outcomes for perioperative durvalumab + chemotherapy in stage IIB–IIIB #NSCLC 🫁 Presented by Dr Martin Reck at #WCLC2026 @iaslc.bsky.social Read the article: bit.ly/4cKEb2H
000
Cancer Therapy Advisor @cancertherapyadv.bsky.social · 14/09/2026
New research from #WCLC: TAISHAN-302: Tambotatug Pelitecan Improves OS, PFS as Second-Line Treatment for Relapsed #SCLC 🫁 Presented this weekend at the @iaslc.bsky.social 2026 #WCLC and published in @NEJM Read the full article: bit.ly/4h0XR3x
000
Cancer Therapy Advisor @cancertherapyadv.bsky.social · 14/09/2026
New data from #WCLC26 found adding intercalating gefitinib to adjuvant platinum-based chemotherapy is associated with improved DFS for EGFR-altered #NSCLC! @iaslc.bsky.social 🫁 Read the full article: bit.ly/4xnnn9g
020
Cancer Therapy Advisor @cancertherapyadv.bsky.social · 11/09/2026
The @fda.gov approved 6 treatments for a range of cancers in August! For more information on the latest approvals, and all of the 2026 drug approvals, check out our FDA Roundup with the link below🔽 bit.ly/4z44Gty
021
Cancer Therapy Advisor @cancertherapyadv.bsky.social · 09/09/2026
Good news for #BloodCancerAwarenessMonth! Innovations in the management of #BloodCancers have resulted in almost 26 million life-years saved since 1950, according to research published in Blood Advances. Read the full article here: bit.ly/4yrjcdE
010
Cancer Therapy Advisor @cancertherapyadv.bsky.social · 08/09/2026
The proportion of women aged 21 to 29 who have never been screened for #CervicalCancer is increasing (exceeding 30%)💜 For #GynecologicCancerAwarenessMonth let's encourage newly age-eligible women to get screened and vaccinated! Article: bit.ly/4r24sQ2
000
Cancer Therapy Advisor @cancertherapyadv.bsky.social · 05/09/2026
This #ChildhoodCancerAwarenessMonth, let's focus on making access to care more equitable🎗️ Data from @jamanetworkopen.com found clinician "gatekeeping" may be responsible for low enrollment in clinical trials with Black and Hispanic children. Read more: bit.ly/4xH0kH7
000
Cancer Therapy Advisor @cancertherapyadv.bsky.social · 03/09/2026
🆕 Incidence of new grade 3 or higher TRAEs and readmissions is low in patients with #Melanoma discharged after tumor-infiltrating lymphocyte therapy with lifileucel, according to research published in @jco-asco.bsky.social Read the full article here▶️ bit.ly/4xuBASM
010
Cancer Therapy Advisor @cancertherapyadv.bsky.social · 01/09/2026
September is #BloodCancerAwarenessMonth! The latest @fda.gov approval of Mimrylo is a win for patients with polycythemia vera, a rare blood cancer Read about the approval here: bit.ly/4xQlkfj
000
Cancer Therapy Advisor @cancertherapyadv.bsky.social · 31/08/2026
The Team We Forgot to Build: Getting Employers, Doctors, and Patients on the Same Team🎙️ Lee Lewis, CSO of Health Transformation Alliance, sits down with Val-YOU Based Care host Kimberly Ku in this new episode! 🔊 Listen here: bit.ly/4iBEnoz
000
Cancer Therapy Advisor @cancertherapyadv.bsky.social · 28/08/2026
Of survivors of childhood cancer who were sexually active, 45.6% reported they did not use condoms, compared to 27.2% of matched control individuals. (Source: Cancer) Read the full article here: bit.ly/4carNZG #PediatricCancer #CancerSurvivor #SexualHealth
000
Cancer Therapy Advisor @cancertherapyadv.bsky.social · 27/08/2026
This week, the @fda.gov has accepted for Priority Review the sBLA for dostarlimab-gxly for patients with previously untreated stage II and III mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) locally advanced rectal cancer. Read more: bit.ly/4y0YbpZ
000
Cancer Therapy Advisor @cancertherapyadv.bsky.social · 26/08/2026
In the new episode of Beyond the Charts, a podcast by DeepScribe AI, Kimberly Ku of Val-You Based Care discusses why some clinicians are hesitant about AI use with DeepScribe CEO Matthew Ko. 🎙️ Listen here now, or wherever you find podcasts: bit.ly/4zSNR5g
020
Cancer Therapy Advisor @cancertherapyadv.bsky.social · 25/08/2026
With 2.1M new US cancer cases expected in 2026, demand for #Oncologists is soaring 🩺📊 💰 Avg US Salary: ~$464K 📍 Top Pay: WA ($444K+) & DC ($443K+) 📉 Pay gaps persist by gender & race Read more here: bit.ly/4qA98fN
000
Cancer Therapy Advisor @cancertherapyadv.bsky.social · 24/08/2026
It's been 25 years since the @FDA granted accelerated approval to #Imatinib (Gleevec) for the treatment of chronic myeloid leukemia. Today, small molecule inhibitors are tackling once "undruggable" targets like RAS in solid tumors. Read more: bit.ly/4gkBxBy
010
Cancer Therapy Advisor @cancertherapyadv.bsky.social · 20/08/2026
Over the past 25 years, research on physical activity and #BreastCancer has shown “sustained and accelerated growth,” with a spike in scientific production from 2000 to 2025. Read more about this study from Clinical Oncology here: bit.ly/3U5DaMd
bit.ly
Research on Physical Activity and Breast Cancer Peaked in Past 5 Years
Investigators sought to describe research trends and patterns in the scientific literature related to physical activity and breast cancer.
021
Cancer Therapy Advisor @cancertherapyadv.bsky.social · 20/08/2026
A study in JNCCN shows remotely delivered education and text updates significantly boost skin self-examination rates among #StemCell transplant survivors. Adding physician activation leads to significantly more clinical skin exams. 📱🩺 🔗 bit.ly/4cdcKyr
000
Cancer Therapy Advisor @cancertherapyadv.bsky.social · 18/08/2026
A study in @jamanetworkopen.com reveals a disconnect in pediatric oncology: clinicians cite financial hardship and "gatekeeping" as barriers to trial enrollment for Black & Hispanic children, but parents prioritize care above all costs. 🩺👶 Read more here: bit.ly/4xH0kH7
bit.ly
Clinicians Cite Financial Hardship, “Gatekeeping” as Barriers to Clinical Trial Enrollment in Black and Hispanic Children
In this study, researchers explored factors influencing the enrollment of Black and Hispanic pediatric cancer patients in clinical trials.
010
Cancer Therapy Advisor @cancertherapyadv.bsky.social · 17/08/2026
A study in @jamasurgery.com reveals that wait times from #Cancer diagnosis to first treatment significantly increased between 2012–2023 across 6 major cancers 📊⏱️ To see the data, and to find out what's causing this rise, read here: bit.ly/4ge8yzh
111
Cancer Therapy Advisor @cancertherapyadv.bsky.social · 17/08/2026
New from Cancer Medicine: Immune-related adverse events in advanced #Melanoma patients treated with ICIs are linked to significantly longer survival (mean 17.4 vs 9.8 mos), even for those who stop treatment due to toxicity! 🔬🩺 Read the full story now! bit.ly/4xKQDHL
bit.ly
Immune-Related Toxicity May Signal Therapeutic Efficacy in Advanced Melanoma
Investigators evaluated the relationship between overall survival and discontinuing immune checkpoint inhibitor therapy due to immunological toxicity in patients with metastatic melanoma.
011
Cancer Therapy Advisor @cancertherapyadv.bsky.social · 15/08/2026
Genomic testing in Medicare patients increased from 6.0% in 2016 to 16.7% in 2023, per @jamanetworkopen.com 📊 • 91.4% received no genomic testing • #BreastCancer had the highest overall uptake (28.6%) • #LungCancer led NGS-only testing (9.2%) 🔗 bit.ly/4ge2UgE
022
Cancer Therapy Advisor @cancertherapyadv.bsky.social · 14/08/2026
What do surgical margins need to be in vulvar cancer? A study from @CancerMedicineJ confirms an 8 mm tumor-free margin is the golden threshold. Margins under 8 mm drove local recurrence up to 24.8%, reinforcing 8 mm as the standard for local control.🔽 bit.ly/4gw6LXH
bit.ly
8-MM Margins Are Local Control Benchmark in Vulvar Squamous Cell Carcinoma
Investigators conducted this meta-analysis to establish the optimal tumor-free margin for local control in vulvar squamous cell carcinoma.
010
Cancer Therapy Advisor @cancertherapyadv.bsky.social · 13/08/2026
What could hostage negotiations teach oncologists about patient care? DeepScribe AI CEO Matthew Ko speaks with Dr Kimberly Ku to learn how tactical empathy can be used to strengthen patient relationships on the latest episode of Val-YOU Based Care! 🔗 bit.ly/45mJJMM #CancerCare
021
Cancer Therapy Advisor @cancertherapyadv.bsky.social · 11/08/2026
🆕 On Thursday, the @FDA approved Tudriqev in combination with nivolumab for adults with unresectable advanced cutaneous melanoma who experienced disease progression on a PD-1-blocking antibody-based regimen. Read here for more⬇️ bit.ly/4fPRFfz
011
Cancer Therapy Advisor @cancertherapyadv.bsky.social · 10/08/2026
A growing body of psycho-oncology research underscores the need for greater psychosocial support in oncology. We spoke with experts like Dr Madeline Li from Princess Margaret Hospital @uhn.ca about what this support looks like from clinicians. Read our feature: 🔗 bit.ly/4fBTCfz
011